This is not a news site; it is an intelligence publication. A signal is short by design and answers three questions: what is developing, why it matters, and which Opportunity Radar thesis it touches.
Each appointment and ratification moves a single continental medicines market from treaty language toward something operational, the precondition for collapsing approval timelines.
As SAHPRA and regional bodies draft device and diagnostic rules, the window to understand them before they harden is open now, not later.
The block selloff is giving way to differentiation. Quality issuers punished for their neighbours are where the mispricing now sits.
As budgets tighten, the long-held assumption that first-in-human work must stay offshore is finally, slowly, being questioned.